Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Fishbane

Showing results (81-90 of 234) with videos related to

Pageof 24
Sort By:
Seminars in Dialysis|June 15, 2013
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysisShayan Shirazian, Candace Grant, Ilene Miller, et al.
Clinical Kidney Journal|May 8, 2023
Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefinedSteven Fishbane, Deepa A Malieckal, Ji H Ng
The Annals of Pharmacotherapy|October 15, 2009
Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacistsShaffeeulah Bacchus, Neeta O'Mara, Harold Manley, et al.
The New England Journal of Medicine|April 19, 2013
Peginesatide for anemia in chronic kidney diseaseIain C Macdougall, Steven Fishbane, Anne-Marie Duliege
Seminars in Nephrology|May 29, 2016
Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing HemodialysisHitesh H Shah, Azzour D Hazzan, Steven Fishbane
Current Opinion in Nephrology and Hypertension|June 8, 2015
Novel iron-based phosphate binders in patients with chronic kidney diseaseHitesh H Shah, Azzour D Hazzan, Steven Fishbane
Kidney International Reports|June 20, 2024
Hypoxia-Inducible Factor Stabilizers: an Evolving Role in Post-Transplant AnemiaSteven Fishbane, Ross Jude Cimagala, Volker H Haase
The New England Journal of Medicine|January 14, 2026
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant HypertensionKenar D Jhaveri, Jamie S Hirsch, Steven Fishbane
Clinical Journal of the American Society of Nephrology : CJASN|January 24, 2012
Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatmentAlan S Kliger, Steven Fishbane, Fredric O Finkelstein
Seminars in Dialysis|March 27, 2014
Should target hemoglobin levels in dialysis patients be lowered to 9-10 g/dl?Steven Fishbane, Naveed N Masani, Azzour D Hazzan
Pageof 24

Showing results (81-90 of 234) with videos related to

Sort By:
Pageof 24
Seminars in Dialysis|June 15, 2013
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysisShayan Shirazian, Candace Grant, Ilene Miller, et al.
Clinical Kidney Journal|May 8, 2023
Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefinedSteven Fishbane, Deepa A Malieckal, Ji H Ng
The Annals of Pharmacotherapy|October 15, 2009
Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacistsShaffeeulah Bacchus, Neeta O'Mara, Harold Manley, et al.
The New England Journal of Medicine|April 19, 2013
Peginesatide for anemia in chronic kidney diseaseIain C Macdougall, Steven Fishbane, Anne-Marie Duliege
Seminars in Nephrology|May 29, 2016
Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing HemodialysisHitesh H Shah, Azzour D Hazzan, Steven Fishbane
Current Opinion in Nephrology and Hypertension|June 8, 2015
Novel iron-based phosphate binders in patients with chronic kidney diseaseHitesh H Shah, Azzour D Hazzan, Steven Fishbane
Kidney International Reports|June 20, 2024
Hypoxia-Inducible Factor Stabilizers: an Evolving Role in Post-Transplant AnemiaSteven Fishbane, Ross Jude Cimagala, Volker H Haase
The New England Journal of Medicine|January 14, 2026
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant HypertensionKenar D Jhaveri, Jamie S Hirsch, Steven Fishbane
Clinical Journal of the American Society of Nephrology : CJASN|January 24, 2012
Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatmentAlan S Kliger, Steven Fishbane, Fredric O Finkelstein
Seminars in Dialysis|March 27, 2014
Should target hemoglobin levels in dialysis patients be lowered to 9-10 g/dl?Steven Fishbane, Naveed N Masani, Azzour D Hazzan
Pageof 24